Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Published Five RNAi-Related Patent Applications

Premium

Title: Compositions and Methods for Control of Insect Infestations in Plants

Number: 20060021087

Filed: April 8, 2005

Lead Inventor: James Baum, Monsanto

The invention, the patent application's abstract states, "is directed to controlling pest infestation by inhibiting one or more biological functions in an invertebrate pest. The invention discloses methods and compositions for use in controlling pest infestation by feeding one or more different recombinant double stranded RNA molecules to the pest in order to achieve a reduction in pest infestation through suppression of gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, and to particular combinations of transgenic pesticidal agents for use in protecting plants from pest infestation," the abstract states.


Title: RNA Interference-Mediated Inhibition of Stromal Cell-Derived Factor-1 Gene Expression Using Short Interfering Nucleic Acid

Number: 20060019917

Filed: May 27, 2005

Lead Inventor: Roberto Guerciolini, Sirna Therapeutics

The invention, the patent application's abstract states, "relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of stromal cell-derived factor-1 gene expression and/or activity. The … invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in SDF-1 gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases, and conditions. Specifically, the invention relates to small nucleic acid molecules … capable of mediating or that mediate RNA interference against SDF-1 gene expression," the abstract states. "Such small nucleic acid molecules are useful, for example, in providing compositions for treatment of traits, diseases and conditions that can respond to modulation of SDF-1 expression in a subject, such as ocular disease, cancer and proliferative diseases, and any other disease, condition, trait, or indication that can respond to the level of SDF-1 in a cell or tissue."


Title: RNA Interference-Mediated Inhibition of Protein Tyrosine Phosphatase Gene Expression Using Short Interfering Nucleic Acid

Number: 20060019913

Filed: Jan. 6, 2005

Lead Inventor: James McSwiggen, Sirna Therapeutics

"This invention relates to compounds, compositions, and methods useful for modulating protein tyrosine phosphatase-1B gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of PTP-1B gene expression and/or activity by RNA interference using small nucleic acid molecules. … Such small nucleic acid molecules are useful, for example, for treating, preventing, inhibiting, or reducing obesity, insulin resistance, diabetes in a subject or organism, and for any other disease, trait, or condition that is related to or will respond to the levels of PTP-1B in a cell or tissue, alone or in combination with other treatments or therapies."


Title: Cell-Transfecting Formulations of Small Interfering RNA-Related Compositions and Methods of Making and Use

Number: 20060019912

Filed: Dec. 20, 2004

Lead Inventor: Timothy Burkoth, Chiron

The patent application, its abstract states, covers "compositions incorporating small interfering ribonucleic acid and certain lipid-conjugated polyamide compound-based delivery vehicles that are particularly useful in the delivery siRNA and other polynucleotides to cells. … Methods of making and using the compositions" are also covered.


Title: Methods and Compositions for Detection of Small Interfering RNA and microRNA

Number: 20060019258

Filed: July 20, 2004

Inventor: Joanne Yeakley, Illumina

"The invention provides a method of distinguishing small RNA from mRNA by contacting a biological isolate with a phosphate reactive reagent having a label moiety under conditions wherein the label moiety is preferentially added to the 5' phosphate of small RNA over the 5' cap structure of mRNA and distinguishing the small RNA from the mRNA according to the presence of the label," the patent application's abstract states. "The invention further provides a method of identifying a plurality of different small RNAs by adding a unique extension sequences to different small RNA sequences and identifying the extended small RNA sequences. Furthermore, the invention provides diagnostic methods for determining presence of a disease or condition such as cancer. Also provided are prognostic methods for determining progression of a disease or condition or for monitoring effectiveness of a treatment for a disease or condition."

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.